Evidence map›Paper›PMID 41459481›Full record

ArticleFrontiers in immunology2025

Computational characterization of peptide binding stability to HLA-C allotypes and its association with HIV-1 infection progression and HIV-1 related neurocognitive impairment.

Mauro Voi, Antonella Sangalli, Erica Ginevra Milano, Carola De Martinis, Elisa Orlandi, Stefano Tamburin, Elisa Mantovani, Angela Federico, Massimiliano Lanzafame, Emanuela Lattuada and 12 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Mauro VoiDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Antonella SangalliDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Erica Ginevra MilanoDepartment of Pharmaceutical Sciences, University of Milan, Milan, Italy.
Carola De MartinisDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Elisa OrlandiDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Stefano TamburinDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Elisa MantovaniDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Angela FedericoDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Massimiliano LanzafameUnit of Infectious Diseases, Santa Chiara Hospital, Azienda Provinciale per i Servizi Sanitari, Trento, Italy.
Emanuela LattuadaUnit of Infectious Diseases, Santa Chiara Hospital, Azienda Provinciale per i Servizi Sanitari, Trento, Italy.
Gustavo Adolfo ArgañarazLaboratory of Molecular Neurovirology, Department of Pharmacy, Faculty of Health Science, University of Brasilia, Brasilia, Brazil.
Bosco Christiano Maciel Da SilvaMedical Investigation Laboratory Unit 56 (LIM/56), Faculdade de Medicina FMUSP, University of São Paulo, São Paulo, Brazil.
Alberto Jose Da Silva DuarteMedical Investigation Laboratory Unit 56 (LIM/56), Faculdade de Medicina FMUSP, University of São Paulo, São Paulo, Brazil.
Jorge CassebFaculty of Medicine, Institute of Tropical Medicine, University of São Paulo, São Paulo, Brazil.
Enrique Roberto ArgañarazLaboratory of Molecular Neurovirology, Department of Pharmacy, Faculty of Health Science, University of Brasilia, Brasilia, Brazil.
Marina MalenaU.O.S. Infectious Diseases, Santa Maria della Misericordia Hospital AULSS5, Rovigo, Italy.
Marco AlbaniDepartment of Pharmaceutical Sciences, University of Milan, Milan, Italy.
Alessandra RuggieroDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Maria Grazia RomanelliDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Maria Teresa ValentiDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Giovanni GraziosoDepartment of Pharmaceutical Sciences, University of Milan, Milan, Italy.
Donato ZipetoDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: HLA-C molecules play a critical role in the immune response, particularly in antigen presentation and immune modulation. Methods: To investigate the effect of the most common HLA-C allotypes on the stability of the HLA-C-β-2 microglobulin-peptide complex, we used the NetMHCpan-4.2 bioinformatic tool that predicts peptide binding to MHC class I molecules. This allowed us to predict the probability of a broad set of peptides to be naturally processed, presented on each HLA-C allotype, and ultimately recognised by the immune system, measured by EL-score. By plotting the EL-score against the percentile of the peptide's stability rank position, curves were drawn to illustrate the relative stability of the binding interaction of each HLA-C allotype tested, and the area under the curve was calculated to determine a stability score for each HLA-C variant. Results: This approach permits us to greatly improve the classification of HLA-C allotypes according to their stability, overcoming the previous coarse stable and unstable binary classification. Analysis of two well-characterised HIV-1 patient cohorts, one focused on disease progression and the other on neurocognitive impairment, demonstrated a significant association between unstable HLA-C alleles, faster disease progression, and worse HIV-associated neurocognitive outcomes. Conclusions: These findings underscore the role of HLA-C stability in AIDS progression, suggesting that profiling HLA-C stability may serve as a predictive tool for HIV-1 disease management and assessing neurocognitive risk, with potential implications in personalised medicine.

Indexed as

HIV-1HIV InfectionsHLA-C AntigensPeptidesComputational BiologyDisease ProgressionHumansMaleProtein BindingProtein StabilityHLA-C AntigensPeptidesantigen presentationHANDHIV-1HLA-Cimmune responseneurocognitive disorderspeptide-binding stabilitypersonalized medicine

Identifiers

PMID41459481
PMCPMC12738900

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.